Skip to main content
SpringerLink
Log in

Kollagenosen

  • Chapter
Rheumatologie aus der Praxis

  • 2372 Accesses

Zusammenfassung

Der Begriff wurde von Klemperer unter der Vorstellung geprägt, dass bei diesen Erkrankungen generalisierte Veränderungen des Bindegewebes ursächlich sind. Der Begriff Kollagenose (im Englischen „connective tissue disease“) hat sich erhalten, obwohl man heute weiß, dass das Kollagen bei dieser Krankheitsgruppe weder strukturell noch biochemisch verändert ist. Es sind systemische Autoimmunerkrankungen, die vor allem durch das Vorhandensein von antinukleären Antikörpern (ANA) gekennzeichnet sind.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 44.99
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  1. Aringer M, Hiepe S (2011) Systemischer Lupus erythematodes. Z Rheumatol 70:313–323

    Article  PubMed  CAS  Google Scholar 

  2. Bertsias GK, Ionnidis JPA, Boletis J et al (2008) EULAR recommendations for the management of systemic lupus erythematosus. Report of a task force of the eular standing committee for international clinical studies including therapeutics (ESCISIT). Ann Rheum Dis 67:195–205

    Article  PubMed  CAS  Google Scholar 

  3. Betz-Fischer R, Herzer P, Schneider M (2005) Systemischer Lupus erythematodes. Dsch Med Wochensch 130:251–258

    Google Scholar 

  4. Bootsma H, Spronk P, Derksen R et al (1995) Prevention of relapses in systemic lupus erythematosus. Lancet 345:1595–1599

    Article  PubMed  CAS  Google Scholar 

  5. Calvo-Alén J, Toloza SM, Fernández M et al (2005) Systemic lupus erythematosus in amultiethnic US cohort (LUMINA) XXV. Smoking, older age, disease activity, lupus anticoagulant, and glucocorticoid dose as risk factors for the occurrence of venous thrombosis in lupus patients. Arthritis Rheum 52:2060–2068

    Article  PubMed  Google Scholar 

  6. Cervera R, Khamashta MA, Font J et al (2003) Morbidity and mortality in systemic lupus erythematosus during a 10-year period: a comparison of early and late manifestations in a cohort of 1,000 patients. Medicine (Baltimore) 82:299–308

    Article  Google Scholar 

  7. Chan TM, Li FK, Tang CS et al (2000) Efficacy of mycophenolate mofetil in patients with diffuse proliferative lupus nephritis. Hong Kong-Guangzhou Nephrology Study Group. N Engl J Med 343:1156–1162

    Article  PubMed  CAS  Google Scholar 

  8. Fischer R, Schneider M (2008) Lupus erythematodes-evidenzbasierte Empfehlungen zu überwachung und Therapie. Z Rheumatol 67:491–499

    Article  PubMed  CAS  Google Scholar 

  9. Fischer-Betz R, Schneider M (2007) ModerneTherapie bei systemischen Lupus erythematodes. Z Rheumatol 66:662–671

    Article  PubMed  CAS  Google Scholar 

  10. Gladman D, Ginzler E, Goldsmith C et al (1996) The development and initial validation of the systemic lupus international collaborating clinics/American college of rheumatology damage index for systemic lupus erythematosus. Arthritis Rheum 39:363–369

    Article  PubMed  CAS  Google Scholar 

  11. Hochberg MC (1997) Updating the ACR revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 40:1725

    Article  PubMed  CAS  Google Scholar 

  12. Ginzler EM, Dooley MA, Aranow C et al (2005) Mycophenolate mofetil or intravenous cyclophosphamide for lupus nephritis. N Engl J Med 353:2219–2228

    Article  PubMed  CAS  Google Scholar 

  13. Hiepe F (2008) Azathioprin bei Kollagenosen. Akt Rheumatol DOI: 10.1055/s-2008-1027576

    Google Scholar 

  14. Merill JT, Neuwellt CM, Wallace DJ, Shanahan JC, Latinis KM, Oates JC et al (2010) Efficacy and saftety of Rituximab in moderately to severely active systemic lupus erythematosus: The randomised, double blind, phase II/III systemic lupus erythematosus evaluation of Rituximab trial. Arthritis Rheum 62:223–233

    Google Scholar 

  15. Navarra SV, Guzman RM, Gallacher AE et al (2011) Efficacy and safety of belimumab in patients with systemic lupus erythematosus: a randomised, placebo controlled, phase 3 trial. Lancet 377:721–731

    Article  PubMed  CAS  Google Scholar 

  16. Ruiz-Irastorza G, Ugarte A, Egurbide MV et al (2007) Antimalarialsmay influence the risk of malignancy in systemic lupus erythematosus. Ann Rheum Dis 66:815–817

    Article  PubMed  CAS  Google Scholar 

  17. Sfikakis PP, Boletis JN, Tsokos GC (2005) Rituximab anti-B-cell therapy in systemic lupus erythematosus: pointing to the future. Curr Opin Rheumatol 17:550–557

    Article  PubMed  CAS  Google Scholar 

  18. Tan EM, Cohen AS, Fries JF et al (1982) The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 25:1271–1277

    Article  PubMed  CAS  Google Scholar 

  19. Tsakonas E, Joseph L, Esdaile JM et al (1998) A long-term study of hydroxychloroquine withdrawal on exacerbations in systemic lupus erythematosus. The Canadian Hydroxychloroquine Study Group. Lupus 7:80–85

    Article  PubMed  CAS  Google Scholar 

  20. Wallace DJ, Stohl W, Furie RA, Lisse JR, Mc Kay JD, Merill JT et al (2009) A phase II, randomised, double blind, placebo controlled, dose-ranging study of belimumab in patients with active systemic lupus erythematosus. Arthritis Rheum 61:1168–1178

    Article  PubMed  CAS  Google Scholar 

  21. Wong JM, Esdaile JM (2005) Methotrexate in systemic lupus erythematosus. Lupus 14:101–105

    Article  PubMed  CAS  Google Scholar 

  22. Zuber M, Koch B, Gause A, Pfreundschuh M (1996) Diagnose und Klassifikationskriterien in der Rheumatologie: Kollagenosen. Dtsch Med Wschr 121:913–918

    Article  PubMed  CAS  Google Scholar 

  23. Bloch KJ, Buchanan WW, Wohl MJ, Bunim JJ (1965) Sjögren’s syndrome, a clinical, pathological and serological study of sixty-two cases. Medicine 44:187–231

    Article  PubMed  CAS  Google Scholar 

  24. Chisholm DM, Mason DK (1968) Labial salivary gland biopsy in Sjögren’s disease. J Clin Pathol 21:656–660

    Article  PubMed  CAS  Google Scholar 

  25. Cummins MJ, Papas A, Kammer GM, Fox PC (2003) Treatment of primary Sjogren’s syndrome with low-dose human interferon alfa administered by the oromucosal route: Combined phase III results. Arthritis Rheum 49:585–593

    Article  PubMed  CAS  Google Scholar 

  26. Dörner T (2008) Sjögren-Syndrom. In: Zeidler H, Zacher J, Hiepe F (Hrsg) Interdisziplinäre klinische Rheumatologie, 2._Auflage. Springer, Berlin Heidelberg New York, pp 817–824

    Chapter  Google Scholar 

  27. Dörner T, Gromnica-Ihle E (2006) Sjögren-Syndrom, Kapitel 4.1. In: Rationelle Diagnostik und Therapie in der Inneren Medizin. Elsevier/Urban Fischer, München

    Google Scholar 

  28. Feist E, Dörner T, Hansen A (2007) Indikation und Option neuer immunmodulatorischer Therapien beim Sjögren-Syndrom Z Rheumatol 66:679–685

    Article  PubMed  CAS  Google Scholar 

  29. Fox RI (2005) Sjögren’s syndrome. Lancet 366:321–331

    Article  PubMed  CAS  Google Scholar 

  30. Fox RI, Dixon R, Guarrasi V, Krubel S (1996) Treatment of primary Sjögren’s syndrome with hydroxychloroquin: a retrospective, openlabel study. Lupus 5 [Suppl 1]: S 31–S 36

    Google Scholar 

  31. Hansen A, Lipsky PE, Dörner T (2005) Immunopathogenesis of primary Sjogren’s syndrome: Implications for disease management and therapy. Curr Opin Rheumatol 17:558–565

    Article  PubMed  CAS  Google Scholar 

  32. Meijer J, Meiners P, Vissink A et al (2010) Effective rituximab treatment in primary Sjögren’s syndrome: A randomised, double-blind, placebo controlled trial. Arthritis Rheum 62:960–980

    Article  PubMed  CAS  Google Scholar 

  33. Kassan SS, Thomas TL, Moutsopoulos HM et al (1978) Increased risk of lymphoma in sicca syndrome. Ann Intern Med 89:888–892

    PubMed  CAS  Google Scholar 

  34. Manthorpe R (2005) Wie klassifizieren wir Patienten, bei denen wir ein Sjögren-Syndrom vermuten? Geschichtliche Entwicklung verschiedener Klassifikationen und vermutliche Weiterentwicklung. Akt Rheumatol 30:32–37

    Article  Google Scholar 

  35. Mariette X, Ravaud P, Steinfeld S et al. (2004) Inefficacy of infliximab in primary Sjogren’s syndrome: results of the randomized, controlled Trial of Remicade in Primary Sjogren’s Syndrome (TRIPSS). Arthritis Rheum 50:1270–1276

    Article  PubMed  CAS  Google Scholar 

  36. Pijpe J, van Imhoff GW, Spijkervet FK et al (2005) Rituximab treatment in patients with primary Sjogren’s syndrome: An open-label phase II study. Arthritis Rheum 52:2740–2750

    Article  PubMed  CAS  Google Scholar 

  37. Sankar V, Brennan MT, Kok MR et al (2004) Etanercept in Sjogren’s syndrome: A twelveweek randomized, double-blind, placebo-controlled pilot clinical trial. Arthritis Rheum 50:2240–2245

    Article  PubMed  CAS  Google Scholar 

  38. Sjögren HSC (1933) Zur Kenntnis der Keratoconjunctivitis sicca (Keratitis filiformis bei Hypofunktion der Tränendrüsen). Acta Ophthalmol [Suppl II]: 1–151

    Google Scholar 

  39. Stiller M (2005) Die oraleKomponente des Sjögren-Syndroms — diagnostischeAspekte und zahnmedizinisch-therapeutischeKonsequenzen. Akt Rheumatol 30:41–45

    Article  Google Scholar 

  40. Tomiak C, Dörner T (2006) Sjögren-Syndrom. Z Rheumatol 65:505–519

    Article  PubMed  CAS  Google Scholar 

  41. Vitali C, Bombardieri S, Jonsson R et al (2002) European Study Group on Classification Criteria for Sjogren’s Syndrome. Classification criteria for Sjogren’s syndrome: A revised version of the European criteria proposed by the America-European Consensus Group. Ann Rheum Dis 61:554–558

    Article  PubMed  CAS  Google Scholar 

  42. Zintzaras E, Voulgarelis M, Moutsopoulos HM (2005) The risk of lymphoma development in autoimmune diseases: A meta-analysis. Arch Intern Med 165:2337–2344

    Article  PubMed  Google Scholar 

  43. Abraham DJ, Krieg T, Distler J, Distler O (2009) Overview of pathogenesis of systemic sclerosis. Rheumatology 48 [Suppl 3]:iii 3–7 (Review)

    CAS  Google Scholar 

  44. Blank N, Max R, Lorenz HM (2006) The role of DMARDs in systemic sclerosis therapy. Rheumatology 45 [Suppl 3]:iii 2-4

    Google Scholar 

  45. Barnett AJ (1978) Scleroderma (progressive systemic sclerosis): Progress and course based on a personal series of 118 cases. Med J Aust 2:129–134

    PubMed  CAS  Google Scholar 

  46. Coleiro B, Marshall SE, Denton CP et al (2001) Treatment of Raynaud’s phenomenon with the selective serotonin reuptake inhibitor fluoxetine. Rheumatology (Oxford) 40:1038–1043

    Article  CAS  Google Scholar 

  47. Distler JHW (2008) Primäres und sekundäres Raynaud Phänomen. Z Rheumatol 67:211–219

    Article  PubMed  CAS  Google Scholar 

  48. Fries JF, Hochberg MC, Medsger TA et al and ACR Diagnostic and Therapeutic Criteria Committee (1994) Criteria for rheumatic disease. Different types and different functions. Arthritis Rheum 37:454–462

    Article  PubMed  CAS  Google Scholar 

  49. Fries R, Shariat K, Wilmowsky H von, Bohm M (2005) Sildenafil in the treatment of Raynaud’s phenomenon resistant to vasodilatory therapy. Circulation 112:2980–2985

    PubMed  CAS  Google Scholar 

  50. Fritzler MJ, Kinsella TD, Garbutt E (1980) The CREST syndrome: Adistinct serologic entity with anticentromere antibodies. Am J Med 69:520–526

    Article  PubMed  CAS  Google Scholar 

  51. Furst DE, Clements PJ (2001) D-penicillamine is not an effective treatment in systemic sclerosis. Scand J Rheumatol 30:189–191

    Article  PubMed  CAS  Google Scholar 

  52. Genth E (2008) Systemische Sklerose. In: Zeidler H, Zacher J, Hiepe F (Hrsg) Interdisziplinäre klinische Rheumatologie, 2._Auflage. Springer, Berlin Heidelberg New York, pp 801–816

    Chapter  Google Scholar 

  53. Genth E, Krieg T (2006) Systemische Sklerose — Diagnose und Klassifikation. Z Rheumatol 65:268–274

    Article  PubMed  CAS  Google Scholar 

  54. Hoeper M (2003) Pulmonale arterielle Hypertonie. In: Hoeper M (Hrsg) Endothelin-Rezeptor-Antagonismus als neues Therapieprinzip bei kardiovaskulären Erkrankungen. Uni-Med, Bremen, pp 30–53

    Google Scholar 

  55. Korn JH, Mayes M, Matucci Cerinic M et al (2004) Digital ulcers in systemic sclerosis: Prevention by treatment with bosentan, an oral endothelin receptor antagonist. Arthritis Rheum 50:3985–3993

    Article  PubMed  CAS  Google Scholar 

  56. LeRoy EC, Medsger TA Jr (2001) Criteria for the classification of early systemic sclerosis. J Rheumatol 28:1573–1576

    PubMed  CAS  Google Scholar 

  57. LeRoy EC, Black C, Fleischmajer R et al (1988) Scleroderma (systemic sclerosis): Classification subsets and pathogenesis. J Rheumatol 15:202–205

    PubMed  CAS  Google Scholar 

  58. Lonzetti LS, Joyal F, Raynauld JP et al (2001) Updating the American College of Rheumatology preliminary classification criteria for systemic sclerosis: Addition of severe nailfold capillaroscopy abnormalities markedly increases the sensitivity for limited scleroderma. Arthritis Rheum 44:735–736

    Article  PubMed  CAS  Google Scholar 

  59. Maricq HR, Valter I (2004) A working classification of scleroderma spectrum disorders: a proposal and the results of testing on a sample of patients. Clin Exp Rheumatol 22: S 5–S 13

    Google Scholar 

  60. Masi AT, Rodnan GP, Medsger T et al (1980) Preliminary criteria for the classification of systemic sclerosis (scleroderma). Arthritis Rheum 23:581–590

    Article  Google Scholar 

  61. Medsger TA Jr, Bombardieri S, Czirjak L et al (2003) Assessment of disease severity and prognosis. Clin Exp Rheumatol 21: S 42–S 46

    Google Scholar 

  62. Meyer O (2006) Prognostic markers for systemic sclerosis. Joint Bone Spine 73:490–494

    Article  PubMed  CAS  Google Scholar 

  63. Nadashkevich O, Davis P, Fritzler MJ (2004) A proposal of criteria for the classification of systemic sclerosis. Med Sci Monit 10: CR615–CR621

    PubMed  Google Scholar 

  64. Pavlov-Dolijanovic S, Damjanov NS, Stojanovic RM et al (2011) Scleroderma pattern of nailfold capillary changes as predictive value for the development of a connective tissue disease: a follow up study of 3,029 patients with primary Raynaud’s phenomenon. Rheumatol Int. 2011 sept 8._[Epub ahead of print]

    Google Scholar 

  65. Perera A, Fertig N, Lucas M et al (2007) Clinical subsets, skin thickness progression rate, and serumantibody levels in systemic sclerosis patientswith anti-topoisomerase I antibody. Arthritis Rheum 56:2740–2746

    Article  PubMed  Google Scholar 

  66. Rhew EY, Barr WG (2004) Scleroderma renal crisis: New insights and developments. Curr Rheumatol Rep 6:129–136

    Article  PubMed  Google Scholar 

  67. Riemekasten G, Schulze-Koops H (2005) Medikamentöse vasoaktive Therapien von Mikrozirkulationsstörungen bei rheumatischen Erkrankungen. Z Rheumatol 64:123–136

    Article  PubMed  CAS  Google Scholar 

  68. Riemekasten G, Dragun D (2007) Risikoadaptierte Therapien bei der systemischen Sklerose. Z Rheumatol 66:672–678

    Article  PubMed  CAS  Google Scholar 

  69. Saar P, Müller-Ladner U (2006) Die systemische Sklerose — Eine rheumatologische Herausforderung. Z Rheumatol 65:429–440

    Article  PubMed  CAS  Google Scholar 

  70. Sharp GC, Irvin WS, Tan EM et al (1972) Mixed connective tissue disease. An apparently distinct rheumatic disease syndrome associated with a specific antibody to an extractable nuclear antigen (ENA). Am J Med 52:148–159

    Article  PubMed  CAS  Google Scholar 

  71. Steen V (2003) Predictors of end stage lung disease in systemic sclerosis. Ann Rheum Dis 62:97–99

    Article  PubMed  CAS  Google Scholar 

  72. Steen V, Medsger TA Jr (2003) Predictors of isolated pulmonary hypertension in patients with systemic sclerosis and limited cutaneous involvement. Arthritis Rheum 48:516–522

    Article  PubMed  Google Scholar 

  73. Tan EM, Rodnan GP, Garcia I et al (1980) Diversity of antinuclear antibodies in progressive systemic sclerosis. Arthritis Rheum 23:617–625

    Article  PubMed  CAS  Google Scholar 

  74. Tashkin DP, Elashoff R, Clements PJ et al, Scleroderma Lung Study Research Group (2006) Cyclophosphamide versus placebo in scleroderma lung disease. N Engl J Med 354:2655–2666

    Article  PubMed  CAS  Google Scholar 

  75. Valentini G, Bencivelli W, Bombardieri S et al (2003) European Scleroderma Study Group to define disease activity criteria for systemic sclerosis. III. Assessment of the construct validity of the preliminary activity criteria. Ann Rheum Dis 62:901–903

    Article  PubMed  CAS  Google Scholar 

  76. Zuber JP, Spertini F (2006) Immunological basis of systemic sclerosis. Rheumatology 45[Suppl 3]: iii 23-25

    Google Scholar 

  77. Amato AA, Griggs RC (2003) Treatment of idiopathic inflammatory myopathies. Curr Opin Neurol 16:569–575

    Article  PubMed  CAS  Google Scholar 

  78. Bohan A, Peter JB (1975) Polymyositis and dermatomyositis (first of two parts). N Engl J Med 292:344–347

    Article  PubMed  CAS  Google Scholar 

  79. Bohan A, Peter JB (1975) Polymyositis and dermatomyositis (second of two parts). N Engl J Med 292:403–407

    Article  PubMed  CAS  Google Scholar 

  80. Bunch TW, Worthington JW, Combs JJ et al (1980) Azathioprine with prednisone for polymyositis. A controlled, clinical trial. Ann Intern Med 92:365–369

    PubMed  CAS  Google Scholar 

  81. Burmester GR, Buttgereit F (2008) Dermatomyositis und Polymyositis. In: Zeidler H, Zacher J, Hiepe F (Hrsg) Interdisziplinäre klinische Rheumatologie, 2._Auflage. Springer, Berlin Heidelberg New York, pp 791–797

    Chapter  Google Scholar 

  82. Callen JP, Wortmann RL (2006) Dermatomyositis. Clin Dermatol 24:363–373

    Article  PubMed  Google Scholar 

  83. Kasteler JS, Callen JP (1997) Low-dose methotrexate administered weekly is an effective corticosteroid-sparing agent for the treatment of the cutaneous manifestations of dermatomyositis. J Am Acad Dermatol 36:67–71

    Article  PubMed  CAS  Google Scholar 

  84. Phillips BA, Zilko P, Garlepp MJ, Mastaglia FL (1998) Frequency of relapses in patientswith polymyositis and dermatomyositis. Muscle Nerve 21:1668–1672

    Article  PubMed  CAS  Google Scholar 

  85. Richter J, Iking-Konert C (2007) Aktuelle Therapien der Dermatomyositis und Polymyositis. Z Rheumatol 66:686–682

    Article  PubMed  CAS  Google Scholar 

  86. Spiera R, Kagen L (1998) Extramuscular manifestations in idiopathic inflammatory myopathies. Curr Opin Rheumatol 10:556–561

    Article  PubMed  CAS  Google Scholar 

  87. Stoltenberg-Didinger G, Genth E (2009) Dermatomyositis. Z Rheumatol 68:287–294

    Article  Google Scholar 

  88. Alarcon-Segovia D, Villareal M (1987) Classification and diagnostic criteria for mixed connective tissue disease In: Kaskawa R, Sharp GC (eds) Mixed connective tissue disease and anti-nuclear antibodies. Elsevier, Amsterdam, pp 33–40

    Google Scholar 

  89. Ahringer M, Steiner G, Smolen JS (2005) Does mixed connective tissue disease exist? Yes. Rheum Dis Clin North Am 31:411–442

    Article  Google Scholar 

  90. Gromnica-Ihle E (2008) Mixed connective tissue disease (Sharp-Syndrom). In: Zeidler H, Zacher J, Hiepe F (Hrsg) Interdisziplinäre klinische Rheumatologie, 2._Auflage. Springer, Berlin Heidelberg New York, pp 824–830

    Google Scholar 

  91. Sharp GC, Irvin WS, Tan EM et al (1972) Mixed connective tissue disease. An apparently distinct rheumatic disease syndrome associated with a specific antibody to an extractable nuclear antigen (ENA). Am J Med 52:148–159

    Article  PubMed  CAS  Google Scholar 

  92. Sharp GC (1987) Diagnostic criteria for classification of MCTD. In: Kaskawa R, Sharp GC (eds) Mixed connective tissue disease and anti-nuclear antibodies. Elsevier, Amsterdam, pp 23–32

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Internistischer Rheumatologe, Wels, Österreich

    Dr. Rudolf Puchner

Authors
  1. Dr. Rudolf Puchner
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

Copyright information

© 2012 Springer-Verlag/Wien

About this chapter

Cite this chapter

Puchner, R. (2012). Kollagenosen. In: Rheumatologie aus der Praxis. Springer, Vienna. https://doi.org/10.1007/978-3-7091-1044-7_4

Download citation

  • DOI: https://doi.org/10.1007/978-3-7091-1044-7_4

  • Publisher Name: Springer, Vienna

  • Print ISBN: 978-3-7091-1043-0

  • Online ISBN: 978-3-7091-1044-7

  • eBook Packages: Medicine (German Language)

Publish with us

Policies and ethics

Search

Navigation